Article
The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.
Nature genetics - 1 Mar 2015
Lin Luping, Sabnis Amit J, Chan Elton, Olivas Victor, Cade Lindsay, Pazarentzos Evangelos, Asthana Saurabh, Neel Dana, Yan Jenny Jiacheng, Lu Xinyuan, Pham Luu, Wang Mingxue M, Karachaliou Niki, Cao Maria Gonzalez, Manzano Jose Luis, Ramirez Jose Luis, Torres Jose Miguel Sanchez, Buttitta Fiamma, Rudin Charles M, Collisson Eric A, Algazi Alain, Robinson Eric, Osman Iman, Muñoz-Couselo Eva, Cortes Javier, Frederick Dennie T, Cooper Zachary A, McMahon Martin, Marchetti Antonio, Rosell Rafael, Flaherty Keith T, Wargo Jennifer A, Bivona Trever G
Abstract excerpt
Resistance to RAF- and MEK-targeted therapy is a major clinical challenge. RAF and MEK inhibitors are initially but only transiently effective in some but not all patients with BRAF gene mutation and are largely ineffective in those with RAS gene mutation because of resistance. Through a genetic screen in BRAF-mutant tumor cells, we show that the Hippo pathway effector YAP (encoded by YAP1) acts as a parallel...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.